Biocon, Ltd. remains buoyant on its biosimilars business identifying “clear growth drivers” including the upcoming US launch of biosimilar (b) adalimumab and the anticipated go-ahead for (b) aspart and (b) bevacizumab that are expected build on the segment’s $1bn annual revenue run rate.
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Indian Player Also Confident On Competing With Lucentis
Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.
